Literature DB >> 32170962

Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology.

Silvia Sookoian1,2, Carlos J Pirola1,3, Luca Valenti4, Nicholas O Davidson5.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a burgeoning worldwide epidemic whose etiology reflects multiple interactions between environmental and genetic factors. Here, we review the major pathways and dominant genetic modifiers known to be relevant players in human NAFLD and which may determine key components of the heritability of distinctive disease traits including steatosis and fibrosis. In addition, we have employed general assumptions which are based on known genetic factors in NAFLD to build a systems biology prediction model that includes functional enrichment. This prediction model highlights additional complementary pathways that represent plausible intersecting signaling networks that we define here as an NAFLD-Reactome. We review the evidence connecting variants in each of the major known genetic modifiers (variants in patatin-like phospholipase domain containing 3, transmembrane 6 superfamily member 2, membrane-bound O-acyltransferase domain containing 7, glucokinase regulator, and hydroxysteroid 17-beta dehydrogenase 13) to NAFLD and expand the associated underlying mechanisms using functional enrichment predictions, based on both preclinical and cell-based experimental findings. These major candidate gene variants function in distinct pathways, including substrate delivery for de novo lipogenesis; mitochondrial energy use; lipid droplet assembly, lipolytic catabolism, and fatty acid compartmentalization; and very low-density lipoprotein assembly and secretion. The NAFLD-Reactome model expands these pathways and allows for hypothesis testing, as well as serving as a discovery platform for druggable targets across multiple pathways that promote NAFLD development and influence several progressive outcomes. In conclusion, we summarize the strengths and weaknesses of studies implicating selected variants in the pathophysiology of NAFLD and highlight opportunities for future clinical research and pharmacologic intervention, as well as the implications for clinical practice.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32170962      PMCID: PMC7363530          DOI: 10.1002/hep.31229

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  97 in total

Review 1.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

Review 2.  Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.

Authors:  Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Trends Endocrinol Metab       Date:  2016-12-13       Impact factor: 12.015

3.  Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.

Authors:  Luca Valenti; Mariagrazia Rumi; Enrico Galmozzi; Alessio Aghemo; Benedetta Del Menico; Stella De Nicola; Paola Dongiovanni; Marco Maggioni; Anna Ludovica Fracanzani; Raffaela Rametta; Massimo Colombo; Silvia Fargion
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

4.  PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes.

Authors:  Florentina Negoita; Julia Blomdahl; Sebastian Wasserstrom; Martin E Winberg; Peter Osmark; Sara Larsson; Karin G Stenkula; Mattias Ekstedt; Stergios Kechagias; Cecilia Holm; Helena A Jones
Journal:  J Cell Biochem       Date:  2018-09-01       Impact factor: 4.429

5.  Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride.

Authors:  Stefan Stender; Eriks Smagris; Bo K Lauridsen; Klaus F Kofoed; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Len A Pennacchio; Diane E Dickel; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

6.  The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Authors:  Benedetta Donati; Benedetta Maria Motta; Piero Pingitore; Marica Meroni; Alessandro Pietrelli; Anna Alisi; Salvatore Petta; Chao Xing; Paola Dongiovanni; Benedetta del Menico; Raffaela Rametta; Rosellina Margherita Mancina; Sara Badiali; Anna Ludovica Fracanzani; Antonio Craxì; Silvia Fargion; Valerio Nobili; Stefano Romeo; Luca Valenti
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

7.  Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease.

Authors:  Silvia Sookoian; Diego Flichman; Martin E Garaycoechea; Carla Gazzi; Julio San Martino; Gustavo O Castaño; Carlos J Pirola
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

8.  Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Authors:  P Dongiovanni; S Stender; A Pietrelli; R M Mancina; A Cespiati; S Petta; S Pelusi; P Pingitore; S Badiali; M Maggioni; V Mannisto; S Grimaudo; R M Pipitone; J Pihlajamaki; A Craxi; M Taube; L M S Carlsson; S Fargion; S Romeo; J Kozlitina; L Valenti
Journal:  J Intern Med       Date:  2017-12-27       Impact factor: 8.989

9.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Authors:  Yang-Lin Liu; Helen L Reeves; Alastair D Burt; Dina Tiniakos; Stuart McPherson; Julian B S Leathart; Michael E D Allison; Graeme J Alexander; Anne-Christine Piguet; Rodolphe Anty; Peter Donaldson; Guruprasad P Aithal; Sven Francque; Luc Van Gaal; Karine Clement; Vlad Ratziu; Jean-Francois Dufour; Christopher P Day; Ann K Daly; Quentin M Anstee
Journal:  Nat Commun       Date:  2014-06-30       Impact factor: 14.919

10.  Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.

Authors:  Matthew A Mitsche; Helen H Hobbs; Jonathan C Cohen
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

View more
  24 in total

1.  Active p38α causes macrovesicular fatty liver in mice.

Authors:  Ilona Darlyuk-Saadon; Chen Bai; Chew Kiat Matthew Heng; Nechama Gilad; Wei-Ping Yu; Pei Yen Lim; Amaury Cazenave-Gassiot; Yongliang Zhang; W S Fred Wong; David Engelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 2.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

3.  Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease.

Authors:  Gang Dong; Xiaoquan Huang; Rongxin Chen; Ling Wu; Siyu Jiang; Shiyao Chen
Journal:  Oxid Med Cell Longev       Date:  2022-05-16       Impact factor: 7.310

4.  Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.

Authors:  Valerie Blanc; Jesse D Riordan; Saeed Soleymanjahi; Joseph H Nadeau; ILKe Nalbantoglu; Yan Xie; Elizabeth A Molitor; Blair B Madison; Elizabeth M Brunt; Jason C Mills; Deborah C Rubin; Irene O Ng; Yeonjung Ha; Lewis R Roberts; Nicholas O Davidson
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

5.  Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.

Authors:  Scott A McHenry; Nicholas O Davidson
Journal:  Hepatology       Date:  2021-02-26       Impact factor: 17.425

6.  Genome-wide Association Study of Liver-related Enzymes Suggests Putative Pleiotropic Effects on Diverse Traits and Diseases.

Authors:  Hyun-Seok Kim; Silvia Sookoian; Ruben Hernaez
Journal:  Hepatology       Date:  2021-12       Impact factor: 17.425

Review 7.  Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.

Authors:  Sílvia Vilarinho; Veeral Ajmera; Melanie Zheng; Rohit Loomba
Journal:  Hepatology       Date:  2021-10       Impact factor: 17.298

8.  Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.

Authors:  Elizabeth P Newberry; Zoe Hall; Yan Xie; Elizabeth A Molitor; Peter O Bayguinov; Gregory W Strout; James A J Fitzpatrick; Elizabeth M Brunt; Julian L Griffin; Nicholas O Davidson
Journal:  Hepatology       Date:  2021-05-22       Impact factor: 17.298

9.  Influences of Vitamin D Levels and Vitamin D-Binding Protein Polymorphisms on Nonalcoholic Fatty Liver Disease Risk in a Chinese Population.

Authors:  Min Wang; Minxian Wang; Ru Zhang; Chao Shen; Liuxin Zhang; Yajie Ding; Zongzhe Tang; Hongliang Wang; Wei Zhang; Yue Chen; Jie Wang
Journal:  Ann Nutr Metab       Date:  2022-01-31       Impact factor: 5.923

Review 10.  Targeting hepatocyte carbohydrate transport to mimic fasting and calorie restriction.

Authors:  Jacqueline Kading; Brian N Finck; Brian J DeBosch
Journal:  FEBS J       Date:  2020-07-26       Impact factor: 5.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.